Schizophrenia, the long-acting antipsychotic that halves the injections
For people suffering from schizophrenia, a long-acting injectable (LAI) antipsychotic that halves the dose may soon come onto the market in Europe. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has actually expressed a positive opinion and recommended that a marketing authorization for aripiprazole in injectable formulation in […]